Business Wire

CO-ARROW-ELECTRONICS

9.6.2021 16:02:07 CEST | Business Wire | Press release

Share
Arrow Electronics and ROOQ Team to Innovate Sports Tracking

Global technology solutions provider Arrow Electronics (NYSE:ARW) and ROOQ, an innovator in sports measurement and analytics technology, have teamed up to create the ROOQ BOX, a sensor technology that enables boxers to monitor and review their performance using data that was previously only available under laboratory conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005194/en/

ROOQ BOX comprises a pair of sensors worn within a strap on each wrist. The sensors record the movements made during boxing activity. The data is then analyzed in the accompanying ROOQ app and cloud using machine learning algorithms to provide a precise record of the session. Using this information, boxers and trainers can create a detailed picture of the training session including punch count, punch speeds, variability and punch force. The algorithm has been trained to identify eight different types of punches and to automatically categorize these while filtering out non-boxing specific motions.

The data delivered by the sensor technology, which was inaccessible to athletes until now, provides an invaluable tool to help boxers monitor and improve their performance. This information can be shared with their coaches. In developing the system, ROOQ has drawn on a wide range of experience from within its team including data, software, hardware and firmware specialists, sports scientists and mathematicians as well as boxers and coaches. This experience reaches to the highest level: ROOQ’s chief sports officer, Henry Maske, is an Olympic boxing champion (gold medal, Seoul 1988) and professional world champion (1993 to 1996).

Arrow has been instrumental in leading the project in the firmware and hardware area between the suppliers of components, development and manufacturing services. Also, Arrow’s eInfochips engineering services were utilized in the project. Arrow has used its logistical and supply chain expertise to enable the product to be brought to market, and production scaled, in a smooth and efficient manner.

"This successful collaboration with ROOQ is a perfect example of how expert teams join forces and overcome difficult entrepreneurial challenges together," said Martin Bielesch, president of Arrow’s components business in EMEA. "Arrow's technical and logistical services enabled ROOQ to focus and execute on its leading competencies in delivering a completely new way of capturing diagnostic data in boxing."

Henry Maske sees many advantages in the cooperation between the two companies. "Arrow is a reliable and solution-oriented partner for us. We benefit from their immense experience as well as from their excellent global network.”

Boxing is just the beginning. The training diagnostics technology is universally applicable. Ralf Rüttgers, founder and CEO at ROOQ, is convinced that the application areas of ROOQ are manifold. He said, "Further development and transfer to the fitness market and other related sports, as well as use in the industrial sector, are all possible. Areas such as prevention, safety and health, will play a role in our future training analysis.”

About Arrow Electronics

Arrow Electronics guides innovation forward for over 180,000 leading technology manufacturers and service providers. With 2020 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .

About ROOQ

ROOQ is about to enter the global market with its training analysis technology. The company employs an interdisciplinary team of over 25 people at its headquarters in Aachen, Germany. The technology model founded in 2018, is a novelty for boxing. For the first time, athletes and coaches receive individualized information on their training performance. For more information, visit rooq.de.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye